Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006358 · ClinicalTrials.gov registry record · Phase 2
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00006358 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 44 participants.
The verdict
NCT00006358, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combining temozolomide and thalidomide in treating patients who have recurrent or progressive brain tumor.
Interventions
- DRUG temozolomide
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-06-13 |
| Est. Completion | 2006-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006358
The ClinicalTrials.gov registry entry for NCT00006358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00006358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006358 about?
NCT00006358 is a clinical study titled "Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combining temozolomide and thalidomide in trea...
What is the current status of trial NCT00006358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2000-06-13. Estimated completion is 2006-07-20.
What interventions are being tested in trial NCT00006358?
The interventions under investigation include: temozolomide (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00006358?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.